Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

被引:38
|
作者
Robinson, Jennifer G. [1 ,2 ]
Colhoun, Helen M. [3 ]
Bays, Harold E. [4 ]
Jones, Peter H. [5 ]
Du, Yunling [6 ]
Hanotin, Corinne [8 ]
Donahue, Stephen [7 ]
机构
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Publ Hlth, Dept Med, Iowa City, IA 52242 USA
[3] Univ Dundee, Sch Med, Div Populat Hlth Sci, Dundee, Scotland
[4] Louisville Metab & Atherosclerosis Res Ctr, Louisville, KY USA
[5] Baylor Coll Med, Clin Studies Unit, Houston, TX 77030 USA
[6] Regeneron Pharmaceut Inc, Dept Biostat, Tarrytown, NY 10591 USA
[7] Regeneron Pharmaceut Inc, Dept Clin Sci, Tarrytown, NY 10591 USA
[8] Sanofi, Dept Clin Res, Paris, France
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODY; LOWERING TREATMENT; STATIN THERAPY; LDL-C; PREVENTION; DISEASE; GUIDELINES; METAANALYSIS;
D O I
10.1002/clc.22327
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double-blind, active-comparator, 24-week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, as add-on therapy in approximate to 650 high-cardiovascular (CV)-risk patients whose low-density lipoprotein cholesterol (LDL-C) levels are 100 mg/dL or 70 mg/dL according to the CV-risk category, high and very high CV risk, respectively, with atorvastatin (20-40 mg/d) or rosuvastatin (10-20 mg/d). Patients are randomized to receive alirocumab 75 mg via a single, subcutaneous, 1-mL injection by prefilled pen every 2 weeks (Q2W) as add-on therapy to atorvastatin (20-40 mg) or rosuvastatin (10-20 mg); or to receive ezetimibe 10 mg/d as add-on therapy to statin; or to receive statin up-titration; or to switch from atorvastatin to rosuvastatin (OPTIONS I only). At week 12, based on week 8 LDL-C levels, the alirocumab dose may be increased from 75 mg to 150 mg Q2W if LDL-C levels remain 100 mg/dL or 70 mg/dL in patients with high or very high CV risk, respectively. The primary efficacy endpoint in both studies is difference in percent change in calculated LDL-C from baseline to week 24 in the alirocumab vs control arms. The studies may provide guidance to inform clinical decision-making when patients with CV risk require additional lipid-lowering therapy to further reduce LDL-C levels. The flexibility of the alirocumab dosing regimen allows for individualized therapy based on the degree of LDL-C reduction required to achieve the desired LDL-C level.
引用
收藏
页码:597 / 604
页数:8
相关论文
共 38 条
  • [21] EZETIMIBE/SIMVASTATIN 10/40MG VERSUS ATORVASTATIN 40MG IN HIGH CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY
    Civeira, F.
    Dan, A. G.
    Hing, P. L. K.
    Hanson, M. E.
    Massaad, R.
    Milardo, C.
    Triscari, J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 21 - 21
  • [22] Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial
    Cha, Jung-Joon
    Hong, Soon Jun
    Kim, Ju Hyeon
    Lim, Subin
    Joo, Hyung Joon
    Park, Jae Hyoung
    Yu, Cheol Woong
    Lee, Pil Hyung
    Lee, Seung Whan
    Lee, Cheol Whan
    Moon, Jae Youn
    Lee, Jong-Young
    Kim, Jung-Sun
    Park, Jae Suk
    Lee, Kyounghoon
    Lim, Sang Yup
    Na, Jin Oh
    Cho, Jin-Man
    Kim, Seok Yeon
    Lim, Do-Sun
    AMERICAN HEART JOURNAL, 2023, 261 : 45 - 50
  • [23] Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
    Averna, Maurizio
    Missault, Luc
    Vaverkova, Helena
    Farnier, Michel
    Viigimaa, Margus
    Dong, Qian
    Shah, Arvind
    Johnson-Levonas, Amy O.
    Taggart, William
    Brudi, Philippe
    DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (04): : 262 - 270
  • [24] Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study)
    Ballantyne, Christie M.
    Weiss, Robert
    Moccetti, Tiziano
    Vogt, Anja
    Eber, Bernd
    Sosef, Froukje
    Duffield, Emma
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05): : 673 - 680
  • [25] A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia
    Kim, Ji Bak
    Song, Woo Hyuk
    Park, Jong Sung
    Youn, Tae-Jin
    Park, Yong Hyun
    Kim, Shin-Jae
    Ahn, Sung Gyun
    Doh, Joon-Hyung
    Cho, Yun-Hyeong
    Kim, Jin Won
    PLOS ONE, 2021, 16 (01):
  • [26] Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus
    Vaverkova, H.
    Farnier, M.
    Averna, M.
    Missault, L.
    Viigimaa, M.
    Dong, Q.
    Shah, A.
    Johnson-Levonas, A. O.
    Brudi, P.
    DIABETOLOGIA, 2009, 52 : S279 - S279
  • [27] Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
    Helen M Colhoun
    Jennifer G Robinson
    Michel Farnier
    Bertrand Cariou
    Dirk Blom
    Dean J Kereiakes
    Christelle Lorenzato
    Robert Pordy
    Umesh Chaudhari
    BMC Cardiovascular Disorders, 14
  • [28] Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
    Colhoun, Helen M.
    Robinson, Jennifer G.
    Farnier, Michel
    Cariou, Bertrand
    Blom, Dirk
    Kereiakes, Dean J.
    Lorenzato, Christelle
    Pordy, Robert
    Chaudhari, Umesh
    BMC CARDIOVASCULAR DISORDERS, 2014, 14
  • [29] Superiority of the effectiveness of rosuvastatine 10mg in relation to atorvastatine 10mg and Siravastatine 20mg in high risk cardiovascular patients (ARIANE and SOLAIRE studies)
    Valensi, P.
    Chadarevian, R.
    Danchin, N.
    DIABETES & METABOLISM, 2007, 33 : S60 - S60
  • [30] Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
    McCullough, Peter A.
    Ballantyne, Christie M.
    Sanganalmath, Santosh K.
    Langslet, Gisle
    Baum, Seth J.
    Shah, Prediman K.
    Koren, Andrew
    Mandel, Jonas
    Davidson, Michael H.
    AMERICAN JOURNAL OF CARDIOLOGY, 2018, 121 (08): : 940 - 948